276P Safety of pregnancy after early breast cancer in young women with hormone receptor-positive disease: A systematic review and meta-analysis
Year: 2023
Type: article
Study design: Systematic Review
Abstract: Despite increasing evidence on the safety of pregnancy after anticancer treatments in breast cancer survivors, many physicians and patients continue to have concerns about a potential detrimental effect of pregnancy in patients with prior history of hormone receptor-positive breast cancer.
Source: ESMO Open
Institutions: Ospedale Policlinico San Martino, University of Sarajevo, Clinical Center University of Sarajevo, Institut Gustave Roussy, Vall d'Hebron Hospital Universitari, MRC Centre for Reproductive Health, University of Edinburgh, Université Libre de Bruxelles, Hospital Zambrano Hellion, Institut Jules Bordet, European Institute of Oncology, Dana-Farber Cancer Institute
Language: English
Topic: Cancer Risks and Factors
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,290
Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Bayer, GlaxoSmithKline, Sanofi, F. Hoffmann-La Roche, Queen Mary University of London, Bayer Fund, MacroGenics, Seagen, Daiichi-Sankyo, Astellas Pharma, Genentech, Takeda Oncology, Pharmaceuticals Bayer, Daiichi Sankyo Europe
OpenAlex ID: W4376613670